Development and Validation of an Immunoassay for Quantification of Topoisomerase I in Solid Tumor Tissues

@inproceedings{Pfister2012DevelopmentAV,
  title={Development and Validation of an Immunoassay for Quantification of Topoisomerase I in Solid Tumor Tissues},
  author={Thomas D. Pfister and Melinda G. Hollingshead and Robert J. Kinders and Yiping Zhang and Yvonne A. Evrard and Jiuping Jay Ji and Sonny A. Khin and Suzanne D. Borgel and Howard Stotler and John Franklin Carter and Raymond D. Divelbiss and Shivaani Kummar and Yves Pommier and Ralph E. Parchment and Joseph Edward Tomaszewski and James H. Doroshow},
  booktitle={PloS one},
  year={2012}
}
BACKGROUND Topoisomerase I (Top1) is a proven target for cancer therapeutics. Recent data from the Fluorouracil, Oxaliplatin, CPT-11: Use and Sequencing (FOCUS) trial demonstrated that nuclear staining of Top1 correlates with chemotherapeutic efficacy. Such a correlation may help identify patients likely to respond to Top1 inhibitors and illuminate their mechanism of action. Cellular response to Top1 inhibitors is complex, but Top1 target engagement is a necessary first step in this process… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 48 REFERENCES

Similar Papers

Loading similar papers…